Wu Yen-Zung, Huang Hsuan-Ti, Cheng Tsung-Lin, Lu Yen-Mou, Lin Sung-Yen, Ho Cheng-Jung, Lee Tien-Ching, Hsu Chia-Hao, Huang Peng-Ju, Huang Han Hsiang, Li Jhong-You, Su Yu-De, Chen Shih-Chieh, Kang Lin, Chen Chung-Hwan
Orthopaedic Research Center, Kaohsiung Medical University, Kaohsiung 80701, Taiwan.
Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80701, Taiwan.
Int J Mol Sci. 2021 May 15;22(10):5232. doi: 10.3390/ijms22105232.
MicroRNAs (miRNAs) could serve as ideal entry points to the deregulated pathways in osteoporosis due to their relatively simple upstream and downstream relationships with other molecules in the signaling cascades. Our study aimed to give a comprehensive review of the already identified miRNAs in osteoporosis from human blood samples and provide useful information for their clinical application. A systematic literature search for relevant studies was conducted in the Pubmed database from inception to December 2020. We set two essential inclusion criteria: human blood sampling and design of controlled studies. We sorted the results of analysis on human blood samples according to the study settings and compiled the most promising miRNAs with analyzed diagnostic values. Furthermore, in vitro and in vivo evidence for the mechanisms of the identified miRNAs was also illustrated. Based on both diagnostic value and evidence of mechanism from in vitro and in vivo experiments, miR-23b-3p, miR-140-3p, miR-300, miR-155-5p, miR-208a-3p, and miR-637 were preferred candidates in diagnostic panels and as therapeutic agents. Further studies are needed to build sound foundations for the clinical usage of miRNAs in osteoporosis.
由于微小RNA(miRNA)在信号级联反应中与其他分子的上下游关系相对简单,它们可能成为骨质疏松症中失调通路的理想切入点。我们的研究旨在全面综述已从人类血液样本中鉴定出的与骨质疏松症相关的miRNA,并为其临床应用提供有用信息。从数据库建立到2020年12月,我们在PubMed数据库中对相关研究进行了系统的文献检索。我们设定了两个基本纳入标准:人类血液采样和对照研究设计。我们根据研究设置对人类血液样本的分析结果进行了分类,并汇总了具有分析诊断价值的最有前景的miRNA。此外,还阐述了已鉴定的miRNA作用机制的体外和体内证据。基于体外和体内实验的诊断价值和作用机制证据,miR-23b-3p、miR-140-3p、miR-300、miR-155-5p、miR-208a-3p和miR-637是诊断组和治疗药物的首选候选物。需要进一步的研究为miRNA在骨质疏松症临床应用中奠定坚实基础。